WO2012147578A1 - 白血球の分類計数方法、白血球分類試薬キット及び白血球分類試薬 - Google Patents
白血球の分類計数方法、白血球分類試薬キット及び白血球分類試薬 Download PDFInfo
- Publication number
- WO2012147578A1 WO2012147578A1 PCT/JP2012/060432 JP2012060432W WO2012147578A1 WO 2012147578 A1 WO2012147578 A1 WO 2012147578A1 JP 2012060432 W JP2012060432 W JP 2012060432W WO 2012147578 A1 WO2012147578 A1 WO 2012147578A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reagent
- less
- concentration
- organic acid
- aromatic organic
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 211
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims abstract description 30
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 79
- -1 aromatic organic acid Chemical class 0.000 claims abstract description 65
- 239000012472 biological sample Substances 0.000 claims abstract description 44
- 239000000523 sample Substances 0.000 claims abstract description 35
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 33
- 238000005259 measurement Methods 0.000 claims abstract description 33
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 18
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 15
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 15
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 15
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 13
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 12
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 7
- 230000001678 irradiating effect Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- 238000010186 staining Methods 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 230000002934 lysing effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 description 57
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 32
- 210000001616 monocyte Anatomy 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000000601 blood cell Anatomy 0.000 description 11
- 210000001167 myeloblast Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 210000003979 eosinophil Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 239000003219 hemolytic agent Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000004065 semiconductor Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000012128 staining reagent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- GZFVOFMKXXTWQE-UHFFFAOYSA-N 3,8-diazido-5-ethyl-6-phenylphenanthridin-5-ium Chemical compound C12=CC(N=[N+]=[N-])=CC=C2C2=CC=C(N=[N+]=[N-])C=C2[N+](CC)=C1C1=CC=CC=C1 GZFVOFMKXXTWQE-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- DPXHITFUCHFTKR-UHFFFAOYSA-L To-Pro-1 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 DPXHITFUCHFTKR-UHFFFAOYSA-L 0.000 description 1
- BCTNMRNAMOIDHS-UHFFFAOYSA-N To-Pro-1(2+) Chemical compound S1C2=CC=CC=C2[N+](C)=C1C=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 BCTNMRNAMOIDHS-UHFFFAOYSA-N 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 description 1
- RUIOCPBCVXVVMB-UHFFFAOYSA-N ToTo-1(4+) Chemical compound C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 RUIOCPBCVXVVMB-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical group [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1468—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle
- G01N15/147—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/011—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells with lysing, e.g. of erythrocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
Definitions
- the present invention relates to a method for classifying and counting white blood cells in a biological sample.
- the present invention also relates to a white blood cell classification reagent kit and a white blood cell classification reagent for classifying and counting white blood cells in a biological sample.
- Normal white blood cells are usually classified into five types: lymphocytes, monocytes, neutrophils, eosinophils and basophils. In normal peripheral blood, these blood cells are present at a certain ratio. However, certain blood counts may increase or decrease if the subject has a disease. Therefore, in the field of clinical examination, it is possible to obtain extremely useful information for diagnosing diseases by performing leukocyte classification and counting.
- lymphocytes In diseases such as hematopoietic tumors and viral infections, cells that do not exist in normal peripheral blood appear. For example, in acute leukemia, immature leukocytes, “blasts (myeloblasts: lymphoblasts)” appear in peripheral blood. On the other hand, for viral infections, drug allergies, etc., atypical lymphocytes (atypical lymphocytes activated by antigen stimulation) lymphocyte) "appears in the peripheral blood. Differentiating and detecting atypical lymphocytes and blasts from peripheral blood is extremely useful for screening or diagnosing diseases.
- Patent Document 1 describes a method capable of classifying and counting both abnormal white blood cells and normal white blood cells.
- a reagent kit comprising a combination of a staining solution that specifically stains RNA and a hemolytic agent containing a cationic surfactant and a nonionic surfactant is used.
- Patent Document 2 describes a method of classifying and counting normal white blood cells and detecting abnormal white blood cells.
- a reagent containing a staining solution containing a predetermined fluorescent dye and a hemolytic agent containing a cationic surfactant and a nonionic surfactant is used.
- a specimen obtained from a subject may contain abnormal white blood cells such as blasts and atypical lymphocytes in addition to normal white blood cells.
- abnormal white blood cells such as blasts and atypical lymphocytes
- the signals of blasts and abnormal lymphocytes which are abnormal leukocytes, appear in almost the same region on the scattergram. It may be difficult to distinguish and detect a sphere.
- An object of the present invention is to provide a method for classifying and counting leukocytes which can classify and count normal leukocytes and which can distinguish and detect blasts and atypical lymphocytes.
- Another object of the present invention is to provide a white blood cell classification reagent kit and a white blood cell classification reagent capable of classifying and counting normal white blood cells and distinguishing and detecting blasts and atypical lymphocytes.
- the blast and atypical lymphocyte signals overlap or overlap with the region where normal and normal monocyte signals appear on the scattergram. Appears in the area to be.
- the present inventors can separate the abnormal leukocyte signal from the normal leukocyte signal by separating the region where the normal lymphocyte signal appears from the region where the normal monocyte signal appears. I thought that it might be possible to raise.
- the present inventors examined a leukocyte classification method capable of separating a region where normal lymphocyte signals appear from a region where normal monocyte signals appear.
- the detection accuracy of abnormal leukocytes is enhanced by distinguishing between blasts and atypical lymphocytes by combining the concentration of the aromatic organic acid and the pH of the reagent in a predetermined combination.
- the present invention has been completed.
- the present invention A cationic reagent and a nonionic surfactant for lysing red blood cells and damaging red blood cells so that the fluorescent dye can penetrate the biological sample, a first reagent for staining nucleic acid, and 20 mM
- the concentration of the aromatic organic acid in the second reagent is 20 mM or more and less than 30 mM
- the pH of the second reagent is 5.5 or more and 6.4 or less
- the aromatic organic acid in the second reagent When the concentration is 30 mM or more and 50 mM or less, the leukocyte classification
- the present invention also includes a first reagent containing a fluorescent dye capable of staining a nucleic acid, a cationic surfactant for lysing red blood cells and damaging the white blood cell membrane so that the fluorescent dye can permeate.
- the second reagent has a pH of 5.5 or more and 6.4 or less, and the concentration of the aromatic organic acid in the second reagent is 30 mM or more and 50 mM or less, the second reagent has a pH of 5.5 or more and 7.0 or less.
- a reagent kit is provided.
- the present invention further provides a leukocyte classification reagent comprising a fluorescent dye capable of staining a nucleic acid, a cationic surfactant, a nonionic surfactant, and an aromatic organic acid, the fragrance contained in the reagent.
- a leukocyte classification reagent comprising a fluorescent dye capable of staining a nucleic acid, a cationic surfactant, a nonionic surfactant, and an aromatic organic acid, the fragrance contained in the reagent.
- concentration of aromatic organic acid is 20 mM or more and 50 mM or less
- the concentration of aromatic organic acid is 20 mM or more and less than 30 mM
- the pH is 5.5 or more and 6.4 or less
- the concentration of aromatic organic acid is 30 mM or more and 50 mM or less.
- a leukocyte classification reagent characterized by having a pH of 5.5 to 7.0 is provided.
- leukocyte classification reagent kit and leukocyte classification reagent of the present invention normal leukocytes can be classified and counted, and blasts and atypical lymphocytes can be distinguished and detected.
- FIG. 10 is a scattergram when a normal blood sample is measured using each reagent of Example 5.
- the biological sample is not particularly limited as long as it is a body fluid sample containing leukocytes.
- biological samples include blood, bone marrow fluid, urine collected from mammals, preferably humans, samples collected by apheresis, and the like.
- the biological sample may also be a sample that may contain abnormal white blood cells.
- the white blood cells in the present invention include normal white blood cells and abnormal white blood cells. Normal white blood cells are usually lymphocytes, monocytes, eosinophils, and granulocytes other than eosinophils, or lymphocytes, monocytes, neutrophils, eosinophils, and eosinophils. There are five types of base spheres.
- abnormal leukocytes mean leukocytes that are not usually present in peripheral blood.
- abnormal leukocytes include atypical lymphocytes and blasts.
- Atypical lymphocytes are lymphocytes activated by antigen stimulation, and indicate morphological changes in response to stimulation. These atypical lymphocytes appear in the peripheral blood of patients with diseases such as viral infections and drug allergies.
- a blast refers to immature leukocytes such as myeloblasts and lymphblasts. Myeloblasts appear in the peripheral blood of patients with acute myeloid leukemia, and lymphoblasts appear in the peripheral blood of patients with acute lymphocytic leukemia.
- the leukocyte classification reagent kit of the present invention (hereinafter sometimes referred to as “reagent kit”) is a kit containing a first reagent and a second reagent. Below, each reagent of a reagent kit is demonstrated.
- the first reagent contained in the reagent kit of the present invention contains a fluorescent dye capable of staining a nucleic acid.
- the first reagent is a reagent for fluorescent staining of nucleic acid of nucleated cells in a biological sample treated with a second reagent described later.
- the fluorescent dye is not particularly limited as long as it is a dye capable of staining a nucleic acid, and can be appropriately selected according to the wavelength of light emitted from a light source.
- fluorescent dyes include propidium iodide, ethidium bromide, ethidium-acridine heterodimer, ethidium diazide, ethidium homodimer-1, ethidium homodimer-2, ethidium monoazide, trimethylenebis [[3-[[ 4-[[[(3-Methylbenzothiazol-3-ium) -2-yl] methylene] -1,4-dihydroquinolin] -1-yl] propyl] dimethylaminium] tetraiodide (TOTO-1), 4 -[(3-Methylbenzothiazole-2 (3H) -ylidene) methyl] -1- [3- (trimethylaminio) prop
- R 1 and R 4 are the same or different from each other, and are a hydrogen atom, an alkyl group, an alkyl chain having a hydroxy group, an alkyl chain having an ether group, an alkyl chain having an ester group, or a substituent.
- R 2 and R 3 are the same or different from each other, and are a hydrogen atom, a hydroxyl group, a halogen, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylsulfonyl group, or Z is a carbon atom having a sulfur atom, an oxygen atom or a methyl group; n is 0, 1, 2 or 3; and X ⁇ is an anion.
- the alkyl group may be linear or branched.
- the other is a hydrogen atom or an alkyl group having less than 6 carbon atoms. It is preferably a group.
- alkyl groups having 6 to 18 carbon atoms alkyl groups having 6, 8 or 10 carbon atoms are preferable.
- a substituent for the benzyl group of R 1 and R 4 for example, an alkyl group having 1 to 20 carbon atoms, an alkenyl group having 2 to 20 carbon atoms, or carbon Examples thereof include alkynyl groups of 2 to 20. Among these, a methyl group or an ethyl group is particularly preferable.
- examples of the alkenyl group represented by R 2 and R 3 in the above formula (I) include alkenyl groups having 2 to 20 carbon atoms.
- examples of the alkoxy group of R 2 and R 3 include an alkoxy group having 1 to 20 carbon atoms. Among these, a methoxy group or an ethoxy group is particularly preferable.
- halogen ions such as F ⁇ , Cl ⁇ , Br ⁇ and I ⁇ , CF 3 SO 3 ⁇ , BF 4 ⁇ and the like can be used. Can be mentioned.
- the fluorescent dye in the first reagent may be one type or two or more types.
- the concentration of the fluorescent dye in the first reagent can be appropriately set according to the type of the fluorescent dye, but is usually 0.01 to 100 pg / ⁇ L, preferably 0.1 to 10 pg / ⁇ L.
- the concentration of the fluorescent dye in the first reagent is preferably 0.2 to 0.6 pg / ⁇ L, more preferably Is 0.3 to 0.5 pg / ⁇ L.
- the first reagent can be obtained by dissolving the fluorescent dye in an appropriate solvent so as to have the above concentration.
- a solvent will not be specifically limited if said fluorescent dye can be dissolved,
- the organic solvent include alcohol, ethylene glycol, dimethyl sulfoxide (DMSO) and the like. Since the fluorescent dye may have poor storage stability in an aqueous solution, it is preferably dissolved in an organic solvent.
- a commercially available staining reagent for leukocyte measurement may be used as the first reagent.
- An example of such a staining reagent is Stoma Riser 4DS (Sysmex Corporation).
- Stoma riser 4DS is a staining reagent containing the fluorescent dye represented by the above formula (I).
- the second reagent contained in the reagent kit of the present invention is a surfactant for lysing erythrocytes and damaging the leukocyte cell membrane to the extent that the fluorescent dye can permeate, that is, a cationic surfactant and a nonionic interface.
- a surfactant for lysing erythrocytes and damaging the leukocyte cell membrane to the extent that the fluorescent dye can permeate that is, a cationic surfactant and a nonionic interface.
- the second reagent further contains an aromatic organic acid at a concentration of 20 mM to 50 mM.
- the pH of the second reagent when the concentration of the aromatic organic acid in the second reagent is 20 mM or more and less than 30 mM, the pH of the second reagent is 5.5 or more and 6.4 or less, more preferably 5.5 or more and 6.2 or less. is there.
- the concentration of the aromatic organic acid in the second reagent is 30 mM or more and 50 mM or less, preferably 40 mM or more and 50 mM or less
- the pH of the second reagent is 5.5 or more and 7.0 or less. More preferably, when the concentration of the aromatic organic acid in the second reagent is 40 mM or more and 50 mM or less, the pH of the second reagent is 5.5 or more and 6.2 or less.
- the red blood cells in the biological sample are hemolyzed, and the above-mentioned fluorescent dye is damaged to the cell membrane of the white blood cells.
- the second reagent can damage the cell membrane of the abnormal leukocytes to such an extent that the fluorescent dye can pass therethrough. Blood cells damaged in the cell membrane by the second reagent are stained with the fluorescent dye in the first reagent.
- the normal lymphocyte signal appearance region and the normal monocyte signal appearance region detected by a flow cytometer or the like Can be separated to such an extent that the detection accuracy of abnormal leukocytes is increased and discrimination between blasts and atypical lymphocytes is possible.
- an aromatic organic acid means an acid having at least one aromatic ring in the molecule and a salt thereof.
- the aromatic organic acid include aromatic carboxylic acid and aromatic sulfonic acid.
- phthalic acid, benzoic acid, salicylic acid, hippuric acid, p-aminobenzenesulfonic acid, benzenesulfonic acid and salts thereof are preferably used as the aromatic organic acid.
- the aromatic organic acid in the second reagent may be one type or two or more types. When two or more types of aromatic organic acids are contained in the second reagent, the total concentration of the aromatic organic acids in the second reagent may be 20 mM or more and 50 mM or less.
- quaternary ammonium salt type surfactant or a pyridinium salt type surfactant can be used as the cationic surfactant.
- examples of the quaternary ammonium salt type surfactant include surfactants having a total carbon number of 9 to 30 and represented by the following formula (II).
- R 1 is an alkyl group or alkenyl group having 6 to 18 carbon atoms
- R 2 and R 3 are the same or different from each other, and are an alkyl group or alkenyl group having 1 to 4 carbon atoms.
- R 4 is an alkyl group or alkenyl group having 1 to 4 carbon atoms, or a benzyl group;
- X ⁇ is a halogen ion;
- R 1 is preferably an alkyl group or alkenyl group having 6, 8, 10, 12 and 14 carbon atoms, and particularly preferably a linear alkyl group. More specific R 1 includes an octyl group, a decyl group, and a dodecyl group.
- R 2 and R 3 are preferably a methyl group, an ethyl group and a propyl group.
- R 4 is preferably a methyl group, an ethyl group or a propyl group.
- pyridinium salt type surfactant examples include surfactants represented by the following formula (III).
- R 1 is an alkyl group or alkenyl group having 6 to 18 carbon atoms;
- X ⁇ is a halogen ion.
- R 1 is preferably an alkyl group or alkenyl group having 6, 8, 10, 12 and 14 carbon atoms, and particularly preferably a linear alkyl group. More specific R 1 includes an octyl group, a decyl group, and a dodecyl group.
- the concentration of the cationic surfactant in the second reagent can be appropriately adjusted depending on the type of the surfactant, but is usually 10 to 10,000 ppm, preferably 100 to 1000 ppm.
- the nonionic surfactant is preferably a polyoxyethylene nonionic surfactant represented by the following formula (VI).
- VI polyoxyethylene nonionic surfactant represented by the following formula (VI).
- R 1 is an alkyl group, alkenyl group or alkynyl group having 8 to 25 carbon atoms;
- R 2 is an oxygen atom, —COO— or
- N is an integer from 10 to 50.
- nonionic surfactant examples include polyoxyethylene alkyl ether, polyoxyethylene sterol, polyoxyethylene castor oil, polyoxyethylene sorbite fatty acid ester, polyoxyethylene alkylamine, polyoxyethylene polyoxypropylene alkyl Examples include ether.
- the concentration of the nonionic surfactant in the second reagent is usually 10 to 100,000 ppm, preferably 100 to 10,000 ppm, more preferably 1000 to 5000 ppm.
- the second reagent may contain a buffering agent in order to keep the pH constant.
- a buffering agent examples include citrate, HEPES and phosphate.
- the aromatic organic acid may have a buffering action. When such an aromatic organic acid is used, addition of a buffering agent to the second reagent is optional.
- the osmotic pressure of the second reagent is not particularly limited, but is preferably 20 to 150 mOsm / kg from the viewpoint of efficiently lysing red blood cells.
- the second reagent contains the surfactant and the aromatic organic acid or a salt thereof, and optionally the buffer, so that the concentration of the aromatic organic acid becomes the above. It can be obtained by dissolving in an appropriate solvent and adjusting the pH with NaOH, HCl or the like.
- the solvent is not particularly limited as long as the above components can be dissolved, and examples thereof include water, organic solvents, and mixtures thereof.
- the organic solvent include alcohol, ethylene glycol, DMSO and the like.
- the above-described reagent kit is divided into a first reagent and a second reagent.
- the present invention is not limited to this, and the reagent kit is not particularly limited as long as the reagent includes the composition of the first reagent and the second reagent.
- the leukocyte classification reagent kit of the present invention or the reagent described above is used, leukocytes in a biological sample can be classified and counted.
- a method for classifying and counting leukocytes using the reagent kit of the present invention hereinafter sometimes simply referred to as “method”.
- measurement is performed by mixing a biological sample with the first reagent and the second reagent of the above-described reagent kit to lyse erythrocytes in the biological sample and stain leukocyte nucleic acid.
- a sample is prepared (preparation process).
- the mixing of the biological sample and the first reagent or the second reagent is performed so that the volume ratio of the biological sample: the first reagent or the second reagent is 1: 1 to 1: 1000, more preferably 1:10 to 1: 100.
- the ratio of the mixture of the first reagent and the second reagent to the biological sample is such that the volume ratio of the biological sample: mixture is 1: 5 to 1: 1000, more preferably 1:10 to 1: 100.
- the order of mixing the biological sample with the first reagent and the second reagent is not particularly limited.
- the first reagent and the second reagent may be mixed first, and this mixed solution and the biological sample may be mixed.
- the second reagent and the biological sample may be mixed first, and the mixed solution and the first reagent may be mixed.
- an equivalent result can be obtained by mixing in any order.
- the temperature is 15 to 50 ° C., preferably 30 to 45 ° C., for 5 to 120 seconds, preferably 5 to 30 seconds. Incubation is preferred.
- the measurement sample prepared in the above step is irradiated with light to acquire scattered light information and fluorescence information (measurement step).
- the measurement step is preferably performed by a flow cytometer.
- scattered light information and fluorescence information can be obtained as signals emitted from the white blood cells by irradiating the white blood cells with light when the stained white blood cells pass through the flow cell of the flow cytometer. .
- the scattered light information is not particularly limited as long as it is a scattered light that can be measured by a commercially available flow cytometer.
- the scattered light information include forward scattered light (for example, around a light receiving angle of 0 to 20 degrees), scattered light pulse width such as side scattered light (around a light receiving angle of about 90 degrees), scattered light intensity, and the like.
- side scattered light reflects internal information such as cell nuclei and granules
- forward scattered light reflects cell size information.
- Fluorescence information is information obtained by irradiating stained white blood cells with excitation light of an appropriate wavelength and measuring the excited fluorescence.
- the fluorescence is emitted from intracellular nucleic acid stained with a fluorescent dye contained in the first reagent.
- the light receiving wavelength can be appropriately selected according to the fluorescent dye contained in the first reagent.
- the light source of the flow cytometer is not particularly limited, and a light source having a wavelength suitable for excitation of the fluorescent dye is selected.
- a light source for example, a red semiconductor laser, a blue semiconductor laser, an argon laser, a He—Ne laser, a mercury arc lamp, or the like is used.
- a semiconductor laser is preferable because it is much cheaper than a gas laser.
- white blood cells in a biological sample are classified and counted based on the scattered light information and fluorescence information (classification counting step).
- white blood cell classification and counting are performed by creating a scattergram having two axes of side scattered light information and fluorescence information, and analyzing the obtained scattergram using appropriate analysis software. Is preferably carried out by For example, when a scattergram is drawn by taking the side scattered light intensity on the X axis and the fluorescence intensity on the Y axis, as shown in the right panel of FIG. 1, leukocytes are lymphocytes, monocytes, neutrophils, It is classified into five types of clusters (clusters) of eosinophils and basophils.
- the analysis software can provide a window surrounding each group on the scattergram, and the number of cells in the window can be counted.
- leukocytes are classified into five types of groups, but the present invention is not limited to this.
- leukocytes may be classified into four types of groups by classifying neutrophils and basophils as one group.
- the biological sample may be a sample that may contain abnormal white blood cells.
- the appearance region of the normal lymphocyte signal detected by the flow cytometer and the appearance region of the normal monocyte signal can be separated on the scattergram. Therefore, in the method of the present invention, when abnormal leukocytes are contained in a biological sample, blasts and atypical lymphocytes can be distinguished and detected among such abnormal leukocytes in the step of classifying and counting leukocytes. .
- the differentiation between blasts and atypical lymphocytes is performed, for example, by setting a signal appearance region of blasts and a signal appearance region of atypical lymphocytes on the scattergram in advance.
- the detection of blasts and atypical lymphocytes is, for example, determined that a blast is contained in a biological sample when a signal is detected in a signal appearance region of a preset blast.
- a signal is detected in the signal appearance region of the atypical lymphocyte, the determination is made that it is determined that the atypical lymphocyte is contained in the biological sample.
- examples of the blast include myeloblast.
- Example 1 in order to separate the position where the signal of normal lymphocyte appears from the position where the signal of normal monocyte appears on the scattergram, the concentration of the aromatic organic acid in the second reagent and the second The pH of the reagent was examined.
- Stoma riser 4DS (Sysmex Corporation) was used as the first reagent.
- the second reagent is dodecyltrimethylammonium chloride (LTAC: Tokyo Chemical Industry Co., Ltd.), polyoxyethylene (30) cetyl ether (BC30TX: Nikko Chemicals Co., Ltd.), potassium hydrogen phthalate (hereinafter referred to as phthalic acid: Wako Pure Chemicals) Kogyo Co., Ltd.) and EDTA-2K (Chubu Crest Co., Ltd.) were mixed and prepared so as to have the composition shown in Table 1 below.
- NaOH solution was used for adjustment of pH.
- LTAC is a cationic surfactant
- BC30TX is a nonionic surfactant
- phthalic acid is an aromatic organic acid.
- the second reagents A and B contain HEPES (Dojindo Laboratories) as a buffer.
- the second reagents A and B correspond to the hemolytic agent of the conventional leukocyte classification reagent.
- the biological sample used in this example is a blood sample (18 samples) collected from 18 healthy persons.
- each specimen is referred to as specimen Nos. 1 to 18, respectively.
- a sample for measurement was prepared by mixing 20 ⁇ L of the sample, 20 ⁇ L of the first reagent and 1000 ⁇ L of the second reagent, and incubating at 40 ° C. for 20 seconds.
- Samples No. 1 to 10 were prepared using second reagents A to D and G to Q, and sample Nos. 11 to 18 were prepared using second reagents B and E to G.
- Each measurement sample was irradiated with light by a flow cytometer (hereinafter referred to as FCM) to detect a side scattered light signal, a forward scattered light signal, and a fluorescent signal emitted from cells in the sample.
- the obtained signal was analyzed to measure normal white blood cells in the measurement sample.
- a red semiconductor laser having an excitation wavelength of 633 nm was used as the light source for the FCM.
- the fluorescence signal detected fluorescence (red fluorescence) having a wavelength of 600 nm or more.
- each white blood cell forms a population for each cell.
- each leukocyte population is identified, the number of cells contained in each leukocyte population, the ratio of the number of cells contained in each leukocyte population to the total number of cells, and each leukocyte population Is calculated.
- the distance between the centroids (hereinafter referred to as the centroid distance) is calculated from the centroid position of each leukocyte population.
- Figure 1 is shown as a reference for the center of gravity distance.
- the left panel of FIG. 1 is a scattergram obtained by measuring a sample of a healthy person using the first reagent and the second reagent O described above. From the left panel of FIG. 1, it is shown that normal white blood cells in the specimen are classified into five types: lymphocytes, monocytes, neutrophils, eosinophils and basophils.
- the right panel of FIG. 1 identifies each classified blood cell population and shows the centroid ( ⁇ ) of the lymphocyte population and the monocyte population. The distance between the two ⁇ is the center of gravity distance.
- the average value of the center-of-gravity distance when measuring 10 specimens (specimen Nos. 1 to 10) using the second reagent A (phthalic acid concentration 20 mM, pH 7.2) was 36.4.
- the average value of the center-of-gravity distance when measuring 18 samples (sample Nos. 1 to 18) using the second reagent B (phthalic acid concentration 20 mM, pH 7.0) was 38.3.
- Table 2 shows the average value of the center-of-gravity distance when measuring 8) and the average value of the center-of-gravity distance when measuring 8 specimens (sample Nos. 11 to 18) using the second reagents E and F. Show.
- Table 3 shows the results of classifying the average value of the center-of-gravity distances shown in Table 2 according to the phthalic acid concentration and pH of each second reagent.
- a combination of phthalic acid concentration and pH is a combination in which the phthalic acid concentration is 20 mM or more and less than 30 mM and the pH is 5.5 or more and 6.4 or less, or the phthalic acid concentration is 30 mM or more and 50 mM or less, And a combination having a pH of 5.5 to 7.0.
- Example 2 In this example, using the first reagent and the second reagent B, G, or O of Example 1, a blood sample containing abnormally shaped lymphocytes (hereinafter referred to as abnormal sample 1) was measured. The measurement by FCM and the calculation of the center-of-gravity distance were performed in the same manner as in Example 1.
- the scattergram (X axis: side scattered light intensity, Y axis: fluorescence intensity) created from the measurement by FCM using each reagent is shown in FIG.
- the center-of-gravity distance when the abnormal specimen 1 was measured using the second reagent B (phthalic acid concentration 20 mM, pH 7.0) was 62.9.
- the center-of-gravity distance when the abnormal sample 1 was measured using the second reagent G (phthalic acid concentration 20 mM, pH 6.0) was 69.7.
- the center-of-gravity distance when the abnormal sample 1 was measured using the second reagent O (phthalic acid concentration 40 mM, pH 6.0) was 80.6.
- the abnormal specimen 1 used in this example is a specimen in which a signal of a lymphocyte with an abnormal morphology appears in the same region as a signal of a normal lymphocyte. Therefore, the population of lymphocytes swells very large on the scattergram.
- the abnormal specimen 1 is measured using the second reagent B, which is a conventional hemolytic agent, a group containing abnormally shaped lymphocytes and a monocyte group overlap to accurately detect abnormally shaped lymphocytes. Difficult to do.
- the second reagent G or O of the reagent kit of the present invention the lymphocyte population and the monocyte population are greatly separated. However, it is possible to accurately separate a population containing abnormally shaped lymphocytes from a population of monocytes. Thereby, it is possible to detect lymphocytes with abnormal morphology with higher accuracy than conventional reagents.
- Example 3 In this example, a biological sample containing abnormally shaped lymphocytes (hereinafter referred to as abnormal specimen 2) and myeloblast using the first reagent and the second reagent B, G, M or O of Example 1 A biological sample (hereinafter, referred to as abnormal specimen 3) was measured.
- abnormal specimen 2 a biological sample containing abnormally shaped lymphocytes
- abnormal specimen 3 A biological sample (hereinafter, referred to as abnormal specimen 3) was measured.
- the biological samples used in this example are two blood samples that cannot be determined whether abnormal leukocytes are abnormal lymphocytes or myeloblasts by measurement with conventional reagents. This is due to the fact that morphologically abnormal lymphocyte and myeloblast signals all appear in almost the same region on the scattergram.
- the measurement by FCM and the calculation of the center-of-gravity distance were performed in the same manner as in Example 1.
- FIG. 3 and 4 show scattergrams (X axis: side scattered light intensity, Y axis: fluorescence intensity) created from measurement by FCM using each reagent.
- the abnormally shaped lymphocyte population contained in the specimen is between the lymphocyte population and the monocyte population. It can be seen that it appears from the region to the upper part of the region (the higher fluorescence intensity).
- the myeloblast population included in the specimen is the same as the abnormal lymphocyte population included in the abnormal specimen 2. It can be seen that it appears in the area. That is, the abnormal leukocyte population contained in the abnormal specimens 2 and 3 partially overlaps with the lymphocyte and monocyte population.
- the abnormal white blood cell populations included in the abnormal specimens 2 and 3 are similar to each other in distribution on the scattergram.
- the second reagent B which is a conventional reagent, whether the specimen contains lymphocytes or myeloblasts with abnormal morphology. Furthermore, since a part of the lymphocyte population with abnormal morphology overlaps the lymphocyte and monocyte population, it is difficult to classify and count normal lymphocytes and monocytes with high accuracy.
- abnormally shaped lymphocytes contained in the abnormal specimen 2 appear biased toward the lymphocyte population, and can be accurately separated from the monocyte population.
- myeloblasts contained in the abnormal specimen 3 appear biased toward the monocyte population and can be accurately separated from the lymphocyte population. Therefore, when the measurement is performed using the second reagent of the reagent kit of the present invention, there is a clear difference between the appearance position of abnormally shaped lymphocytes and the appearance position of myeloblasts. It is possible to accurately determine whether it is included.
- abnormal leukocyte populations can be accurately separated from lymphocyte populations or monocyte populations, so that normal monocytes or normal lymphocytes can be classified and counted more accurately than conventional reagents. Can do.
- Example 4 a biological sample containing abnormally shaped lymphocytes was measured using the first reagent and the second reagent A or O of Example 1.
- the abnormal lymphocytes contained in the biological sample of the present example are lymphocytes that have been confirmed to be atypical lymphocytes by morphological examination.
- the biological sample used in the present example has two blood specimens (hereinafter referred to as abnormal specimen 4 and abnormal specimen 5, respectively) that cannot be distinguished whether abnormal leukocytes are atypical lymphocytes or blasts by measurement with conventional reagents. ). As described above, this is because each signal of atypical lymphocyte blast appears in almost the same region on the scattergram.
- the measurement by FCM was performed in the same manner as in Example 1.
- FIG. 5 shows a scattergram (horizontal axis: side scattered light intensity, vertical axis: fluorescence intensity) created from measurement by FCM using each reagent.
- the second reagent A which is a conventional reagent
- the atypical lymphocyte population contained in the specimen is determined from the region between the lymphocyte population and the monocyte population. It can be seen that it appears upward (the higher fluorescence intensity).
- the blast population since the blast population also appears in almost the same region (not shown), the atypical lymphocyte population and the blast population cannot be detected separately.
- Example 5 the first reagent of Example 1, the second reagent A or G as the second reagent, or the second reagent R or S containing phthalic acid and benzoic acid as the aromatic organic acid, The biological sample was used to measure.
- the second reagents R and S were prepared by mixing LTAC, BC30TX, phthalic acid, benzoic acid and EDTA-2K so as to have the composition shown in Table 4 below.
- the biological sample used in this example is a blood sample collected from a healthy person. Measurement by FCM and calculation of the center-of-gravity distance were performed in the same manner as in Example 1.
- FIG. 6 shows a scattergram (horizontal axis: side scattered light intensity, vertical axis: fluorescence intensity) created from measurement by FCM using each reagent.
- Table 5 shows the center-of-gravity distance when the specimen is measured using each reagent, and the concentration and pH of the aromatic organic acid of each reagent.
- the center-of-gravity distance between the monocyte population and the lymphocyte population is further increased by measurement using a second reagent in which benzoic acid is further added to phthalic acid as an aromatic organic acid. I found out that I could do it.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Ecology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Signal Processing (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
lymphocyte)」が末梢血液中に出現する。末梢血液中から異型リンパ球と芽球とを区別して検出することは、疾患のスクリーニング又は診断を行う上で極めて有用である。
しかしながら、特許文献1及び特許文献2の試薬を用いた方法では、異常白血球である芽球及び異型リンパ球のシグナルが、いずれもスキャッタグラム上のほぼ同じ領域に出現するので、芽球と異型リンパ球とを区別して検出することが困難な場合がある。
生体試料と、核酸を染色する第1試薬と、赤血球を溶血させ、白血球の細胞膜に前記蛍光色素が透過できる程度の損傷を与えるための、カチオン性界面活性剤およびノニオン性界面活性剤、ならびに20mM以上50mM以下の濃度で芳香族の有機酸を含有する第2試薬とを混合して測定試料を調製する工程;
調製された測定試料に光を照射し、そのときに生じる散乱光情報および蛍光情報を取得する工程;および
取得された散乱光情報および蛍光情報に基づいて、前記生体試料中の白血球を分類するとともに、芽球と異型リンパ球とを区別して検出する工程;
を含み、前記第2試薬中の芳香族の有機酸の濃度が20mM以上30mM未満の場合は前記第2試薬のpHが5.5以上6.4以下であり、前記第2試薬中の芳香族の有機酸の濃度が30mM以上50mM以下の場合は前記第2試薬のpHが5.5以上7.0以下である、白血球の分類計数方法を提供する。
本発明はさらに、核酸を染色可能な蛍光色素と、カチオン性界面活性剤と、ノニオン性界面活性剤と、芳香族の有機酸と、を含む白血球分類試薬であって、試薬中に含まれる芳香族の有機酸の濃度が20mM以上50mM以下であり、芳香族の有機酸の濃度が20mM以上30mM未満の場合はpHが5.5以上6.4以下であり、芳香族の有機酸の濃度が30mM以上50mM以下の場合はpHが5.5以上7.0以下であることを特徴とする白血球分類試薬を提供する。
本発明の試薬キットに含まれる第1試薬は、核酸を染色可能な蛍光色素を含む。本発明の実施の形態において、第1試薬は、後述する第2試薬により処理された生体試料中の有核細胞の核酸を蛍光染色するための試薬である。生体試料を第1試薬で処理することにより、正常白血球および上記の異常白血球などの核酸を有する血球が染色される。
有機溶媒としては、例えば、アルコール、エチレングリコール、ジメチルスルホキシド(DMSO)などが挙げられる。蛍光色素は、水溶液中での保存安定性が悪い場合があるので、有機溶媒に溶解させることが好ましい。
本発明の試薬キットに含まれる第2試薬は、赤血球を溶血させ、白血球の細胞膜に上記の蛍光色素が透過できる程度の損傷を与えるための界面活性剤、すなわちカチオン性界面活性剤およびノニオン性界面活性剤を含有する。該第2試薬はさらに、20mM以上50mM以下の濃度で芳香族の有機酸を含有する。
第2試薬により細胞膜に損傷を受けた血球は、上記の第1試薬中の蛍光色素により染色される。第2試薬に含まれる芳香族の有機酸の濃度およびpHが上記の範囲内であることにより、フローサイトメータなどにより検出した正常リンパ球のシグナルの出現領域と正常単球のシグナルの出現領域とを、異常白血球の検出精度を高め且つ芽球と異型リンパ球との判別を可能にする程度に隔てることができる。
R1-R2-(CH2CH2O)n-H (VI)
溶媒としては、上記の成分を溶解させることができれば特に限定されないが、例えば水、有機溶媒、および、それらの混合物が挙げられる。有機溶媒としては、例えば、アルコール、エチレングリコール、DMSOなどが挙げられる。
本発明の白血球分類試薬キットまたは上記した試薬を用いれば、生体試料中の白血球を分類計数することができる。以下に、本発明の試薬キットを用いた場合の白血球の分類計数方法(以下、単に「方法」という場合がある。)について説明する。
本発明の方法では、まず、生体試料と、上記の試薬キットの第1試薬および第2試薬と、を混合して、該生体試料中の赤血球を溶解させるとともに白血球の核酸を染色することにより測定試料を調製する(調製工程)。
本発明の実施の形態において、測定工程はフローサイトメータにより行われることが好ましい。フローサイトメータによる測定では、染色された白血球がフローサイトメータのフローセルを通過する際に該白血球に光を照射することにより、該白血球から発せられるシグナルとして散乱光情報および蛍光情報を得ることができる。
当該技術においては、側方散乱光は細胞の核及び顆粒などの内部情報を反映し、前方散乱光は細胞の大きさの情報を反映することが知られている。本発明の実施の形態においては、散乱光情報として側方散乱光強度を用いることが好ましい。
本発明の実施の形態において、白血球の分類計数は、側方散乱光情報と蛍光情報とを二軸とするスキャッタグラムを作成し、得られたスキャッタグラムを適当な解析ソフトを用いて解析することにより行われることが好ましい。例えば、X軸に側方散乱光強度、Y軸に蛍光強度をとってスキャッタグラムを描いた場合、図1の右パネルに示されるように、白血球は、リンパ球、単球、好中球、好酸球および好塩基球の5種類の集団(クラスター)に分類される。そして、解析ソフトによって、スキャッタグラム上で各集団を囲むウィンドウを設け、その中の細胞数を計数することができる。
なお、図1では、白血球を5種類の集団に分類しているが、本発明はこれに限定されない。例えば、好中球と好塩基球とを1つの集団として分類することにより、白血球を4種類の集団に分類してもよい。
本発明の実施形態において、芽球としては、例えば骨髄芽球が挙げられる。
本実施例では、正常リンパ球のシグナルが出現する位置と正常単球のシグナルが出現する位置とをスキャッタグラム上で分離するために、第2試薬中の芳香族の有機酸の濃度と第2試薬のpHとを検討した。
なお、LTACはカチオン性界面活性剤であり、BC30TXはノニオン性界面活性剤であり、フタル酸は芳香族の有機酸である。
各測定用試料にフローサイトメータ(以下、FCMという)により光を照射して、該試料中の細胞から発せられる側方散乱光シグナル、前方散乱光シグナルおよび蛍光シグナルを検出した。得られたシグナルを解析して測定用試料中の正常白血球を測定した。なお、FCMの光源として、励起波長633nmの赤色半導体レーザを用いた。蛍光シグナルは、600nm以上の波長の蛍光(赤蛍光)を検出した。
本実施例では、実施例1の第1試薬と第2試薬B、G又はOとを用いて、形態が異常なリンパ球を含む血液検体(以下、異常検体1という)を測定した。なお、FCMによる測定および重心距離の算出は、実施例1と同様にして行った。
これに対して、本発明の試薬キットの第2試薬G又はOを用いた測定では、リンパ球の集団と単球の集団とが大きく離れるので、本実施例のように異常検体を測定した場合でも、形態が異常なリンパ球を含む集団と単球の集団とを精度よく分けることができるようになる。これにより、従来試薬よりも精度よく形態が異常なリンパ球を検出することができる。
本実施例では、実施例1の第1試薬と第2試薬B、G、MまたはOとを用いて、形態が異常なリンパ球を含む生体試料(以下、異常検体2という)および骨髄芽球を含む生体試料(以下、異常検体3という)を測定した。
すなわち、異常検体2および3に含まれる異常白血球の集団はいずれもリンパ球および単球の集団と一部分が重なっている。また、異常検体2および3に含まれる異常白血球の集団は、スキャッタグラム上での分布の様子が互いに類似している。
したがって、従来試薬である第2試薬Bを用いた測定の結果からは、検体中に形態が異常なリンパ球および骨髄芽球のいずれが含まれているのか判別できない。さらに、形態が異常なリンパ球の集団の一部分がリンパ球および単球の集団と重なっているので、正常なリンパ球および単球を精度よく分類計数することが困難である。
したがって、本発明の試薬キットの第2試薬を用いて測定すれば、形態が異常なリンパ球の出現位置と骨髄芽球の出現位置とに明確な差が現れるので、いずれの異常白血球が検体に含まれているのかを正確に判断することができる。さらに、異常白血球の集団はリンパ球の集団または単球の集団と精度良く分けることができるようになるので、従来の試薬と比べて、正常単球または正常リンパ球をより正確に分類計数することができる。
本実施例では、実施例1の第1試薬と第2試薬AまたはOとを用いて、形態が異常なリンパ球を含む生体試料を測定した。ここで、本実施例の生体試料に含まれている形態が異常なリンパ球は、形態学検査により異型リンパ球であると確認されたリンパ球である。
本実施例で用いた生体試料は、従来の試薬による測定では、異常白血球が異型リンパ球であるか芽球であるかを判別できない2つの血液検体(以下、それぞれ異常検体4および異常検体5という)である。これは、上述したように、異型リンパ球芽球の各シグナルがいずれもスキャッタグラム上のほぼ同じ領域に出現することに起因する。なお、FCMによる測定は、実施例1と同様にして行った。
これに対して、第2試薬Oを用いて異常検体4および5を測定すると、単球の集団とリンパ球の集団とが離れるとともに、異型リンパ球の集団はリンパ球の集団へ偏って出現した。上記の実施例3の図4で示したように、第2試薬Oを用いて芽球を含む異常検体を測定した場合、芽球は単球の集団へ偏って出現する。これにより、異型リンパ球の集団と芽球の集団とを区別して検出することができる。
本実施例では、実施例1の第1試薬と、第2試薬として、第2試薬A若しくはG、又は、芳香族の有機酸としてフタル酸および安息香酸を含む第2試薬R若しくはSと、を用いて生体試料を測定した。なお、第2試薬RおよびSは、LTAC、BC30TX、フタル酸、安息香酸およびEDTA-2Kを、以下の表4に示される組成となるように混合して調製した。
Claims (14)
- 生体試料と、核酸を染色する第1試薬と、赤血球を溶血させ、白血球の細胞膜に前記蛍光色素が透過できる程度の損傷を与えるための、カチオン性界面活性剤およびノニオン性界面活性剤、ならびに20mM以上50mM以下の濃度で芳香族の有機酸を含有する第2試薬とを混合して測定試料を調製する工程;
調製された測定試料に光を照射し、そのときに生じる散乱光情報および蛍光情報を取得する工程;および
取得された散乱光情報および蛍光情報に基づいて、前記生体試料中の白血球を分類するとともに、芽球と異型リンパ球とを区別して検出する工程;
を含み、
前記第2試薬中の芳香族の有機酸の濃度が20mM以上30mM未満の場合は前記第2試薬のpHが5.5以上6.4以下であり、前記第2試薬中の芳香族の有機酸の濃度が30mM以上50mM以下の場合は前記第2試薬のpHが5.5以上7.0以下である白血球の分類計数方法。 - 前記芳香族の有機酸が、芳香族カルボン酸、芳香族スルホン酸およびそれらの塩からなる群より選択される少なくとも1つである請求項1に記載の方法。
- 前記第2試薬中の芳香族の有機酸の濃度が、40mM以上50mM以下である請求項1または2に記載の方法。
- 前記第2試薬中のpHが、5.5以上6.2以下である請求項1または2に記載の方法。
- 前記散乱光情報が、側方散乱光情報である請求項1または2に記載の方法。
- 前記カチオン性界面活性剤が、第四級アンモニウム塩型界面活性剤、またはピリジニウム塩型界面活性剤である請求項1または2に記載の方法。
- 核酸を染色可能な蛍光色素を含有する第1試薬と、
赤血球を溶血させ、白血球の細胞膜に前記蛍光色素が透過できる程度の損傷を与えるための、カチオン性界面活性剤およびノニオン性界面活性剤、ならびに20mM以上50mM以下の濃度で芳香族の有機酸を含有する第2試薬とを含み、
前記第2試薬中の芳香族の有機酸の濃度が20mM以上30mM未満の場合は前記第2試薬のpHが5.5以上6.4以下であり、前記第2試薬中の芳香族の有機酸の濃度が30mM以上50mM以下の場合は前記第2試薬のpHが5.5以上7.0以下である白血球分類試薬キット。 - 前記芳香族の有機酸が、芳香族カルボン酸、芳香族スルホン酸およびそれらの塩からなる群より選択される少なくとも1つである請求項8に記載の試薬キット。
- 前記第2試薬中の芳香族の有機酸の濃度が40mM以上50mM以下である、請求項8または9に記載の試薬キット。
- 前記第2試薬中のpHが、5.5以上6.2以下である請求項8または9に記載の試薬キット。
- 前記カチオン性界面活性剤が、第四級アンモニウム塩型界面活性剤、またはピリジニウム塩型界面活性剤である請求項8または9に記載の試薬キット。
- 核酸を染色可能な蛍光色素と、カチオン性界面活性剤と、ノニオン性界面活性剤と、芳香族の有機酸とを含む白血球分類試薬であって、
前記試薬に含まれる芳香族の有機酸の濃度が20mM以上50mM以下であり、
前記芳香族の有機酸の濃度が20mM以上30mM未満の場合はpHが5.5以上6.4以下であり、前記芳香族の有機酸の濃度が30mM以上50mM以下の場合はpHが5.5以上7.0以下であることを特徴とする白血球分類試薬。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280016125.2A CN103460041B (zh) | 2011-04-28 | 2012-04-18 | 白细胞的分类计数方法、白细胞分类试剂盒及白细胞分类试剂 |
SG2013075643A SG194452A1 (en) | 2011-04-28 | 2012-04-18 | Method for classifying/counting leukocytes, reagent kit for classifying leukocytes, and reagent for classifying leukocytes |
EP12776153.4A EP2703812B1 (en) | 2011-04-28 | 2012-04-18 | Method for classifying/counting leukocytes, reagent kit for classifying leukocytes, and reagent for classifying leukocytes |
BR112013027349-6A BR112013027349B1 (pt) | 2011-04-28 | 2012-04-18 | método para classificação/contagem de leucócitos, kit de reagentes para classificação de leucócitos, e reagentes para classificação de leucócitos |
US14/061,333 US20140120530A1 (en) | 2011-04-28 | 2013-10-23 | Method for classifying/counting leukocytes, reagent kit for classifying leukocytes, and reagent for classifying leukocytes |
US16/915,851 US20200326332A1 (en) | 2011-04-28 | 2020-06-29 | Method for classifying/counting leukocytes, reagent kit for classifying leukocytes, and reagent for classifying leukocytes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-101595 | 2011-04-28 | ||
JP2011101595A JP5583629B2 (ja) | 2011-04-28 | 2011-04-28 | 白血球の分類計数方法、白血球分類試薬キット及び白血球分類試薬 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/061,333 Continuation US20140120530A1 (en) | 2011-04-28 | 2013-10-23 | Method for classifying/counting leukocytes, reagent kit for classifying leukocytes, and reagent for classifying leukocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012147578A1 true WO2012147578A1 (ja) | 2012-11-01 |
Family
ID=47072099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/060432 WO2012147578A1 (ja) | 2011-04-28 | 2012-04-18 | 白血球の分類計数方法、白血球分類試薬キット及び白血球分類試薬 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20140120530A1 (ja) |
EP (1) | EP2703812B1 (ja) |
JP (1) | JP5583629B2 (ja) |
CN (1) | CN103460041B (ja) |
BR (1) | BR112013027349B1 (ja) |
SG (1) | SG194452A1 (ja) |
WO (1) | WO2012147578A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016004030A (ja) * | 2014-06-19 | 2016-01-12 | シスメックス株式会社 | 血液分析装置、血液分析方法及び血液分析プログラム |
JP2016515397A (ja) * | 2013-04-19 | 2016-05-30 | エピオンティス ゲーエムベーハー | 生体サンプルにおける定量的細胞組成を特定する方法 |
EP4047348A1 (en) * | 2021-02-22 | 2022-08-24 | Sysmex Corporation | Hemolytic reagent, reagent kit, and method for classifying white blood cells |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6383216B2 (ja) * | 2014-08-08 | 2018-08-29 | シスメックス株式会社 | 血液分析方法、血液分析装置およびプログラム |
JP6238856B2 (ja) | 2014-08-25 | 2017-11-29 | シスメックス株式会社 | 尿中異型細胞の分析方法、尿分析装置および体液中異型細胞の分析方法 |
CN108318408B (zh) * | 2018-01-30 | 2020-04-17 | 深圳唯公生物科技有限公司 | 白细胞分类用样本的预处理试剂及方法 |
CN112424582A (zh) * | 2018-08-29 | 2021-02-26 | 深圳迈瑞生物医疗电子股份有限公司 | 血液样本检测的方法、血液样本检测仪和存储介质 |
CN109238801B (zh) * | 2018-10-19 | 2021-08-13 | 武汉百合龙腾生物科技有限责任公司 | 一种血细胞分析用溶血剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07294518A (ja) * | 1994-04-21 | 1995-11-10 | Toa Medical Electronics Co Ltd | 白血球分析用試薬及び白血球の分類方法 |
JP2002207034A (ja) * | 2001-01-10 | 2002-07-26 | Sysmex Corp | 異常細胞検出方法 |
US20090023129A1 (en) | 2007-07-20 | 2009-01-22 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | White blood cell differentiation reagent and method of use thereof |
JP4248017B2 (ja) | 2005-10-28 | 2009-04-02 | シスメックス株式会社 | 白血球分類計数方法及び白血球分類計数試薬キット |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3783808B2 (ja) * | 1997-05-19 | 2006-06-07 | シスメックス株式会社 | 白血球分類計数用試薬 |
JP4914656B2 (ja) * | 2006-06-26 | 2012-04-11 | シスメックス株式会社 | 試料分析用試薬、試料分析用試薬キット及び試料分析方法 |
PL2202516T3 (pl) * | 2007-09-27 | 2015-02-27 | Sysmex Corp | Zestaw odczynników do analizy próbek i sposób analizy próbek |
CN101470108B (zh) * | 2007-12-24 | 2013-11-27 | 深圳迈瑞生物医疗电子股份有限公司 | 一种对白细胞进行分类的试剂和方法 |
CN101750476B (zh) * | 2008-12-08 | 2015-06-03 | 深圳迈瑞生物医疗电子股份有限公司 | 血液分析试剂及其使用方法 |
CN101750274B (zh) * | 2008-12-17 | 2014-06-25 | 深圳迈瑞生物医疗电子股份有限公司 | 白细胞分类计数试剂、试剂盒以及白细胞分类计数的方法 |
-
2011
- 2011-04-28 JP JP2011101595A patent/JP5583629B2/ja active Active
-
2012
- 2012-04-18 EP EP12776153.4A patent/EP2703812B1/en active Active
- 2012-04-18 WO PCT/JP2012/060432 patent/WO2012147578A1/ja active Application Filing
- 2012-04-18 BR BR112013027349-6A patent/BR112013027349B1/pt active IP Right Grant
- 2012-04-18 CN CN201280016125.2A patent/CN103460041B/zh active Active
- 2012-04-18 SG SG2013075643A patent/SG194452A1/en unknown
-
2013
- 2013-10-23 US US14/061,333 patent/US20140120530A1/en not_active Abandoned
-
2020
- 2020-06-29 US US16/915,851 patent/US20200326332A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07294518A (ja) * | 1994-04-21 | 1995-11-10 | Toa Medical Electronics Co Ltd | 白血球分析用試薬及び白血球の分類方法 |
JP2002207034A (ja) * | 2001-01-10 | 2002-07-26 | Sysmex Corp | 異常細胞検出方法 |
JP4248017B2 (ja) | 2005-10-28 | 2009-04-02 | シスメックス株式会社 | 白血球分類計数方法及び白血球分類計数試薬キット |
US20090023129A1 (en) | 2007-07-20 | 2009-01-22 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | White blood cell differentiation reagent and method of use thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP2703812A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016515397A (ja) * | 2013-04-19 | 2016-05-30 | エピオンティス ゲーエムベーハー | 生体サンプルにおける定量的細胞組成を特定する方法 |
JP2016004030A (ja) * | 2014-06-19 | 2016-01-12 | シスメックス株式会社 | 血液分析装置、血液分析方法及び血液分析プログラム |
EP4047348A1 (en) * | 2021-02-22 | 2022-08-24 | Sysmex Corporation | Hemolytic reagent, reagent kit, and method for classifying white blood cells |
Also Published As
Publication number | Publication date |
---|---|
BR112013027349B1 (pt) | 2021-05-18 |
BR112013027349A2 (pt) | 2017-01-17 |
EP2703812B1 (en) | 2018-02-28 |
US20140120530A1 (en) | 2014-05-01 |
US20200326332A1 (en) | 2020-10-15 |
CN103460041A (zh) | 2013-12-18 |
EP2703812A1 (en) | 2014-03-05 |
EP2703812A4 (en) | 2014-12-10 |
JP2012233754A (ja) | 2012-11-29 |
SG194452A1 (en) | 2013-12-30 |
JP5583629B2 (ja) | 2014-09-03 |
CN103460041B (zh) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012147578A1 (ja) | 白血球の分類計数方法、白血球分類試薬キット及び白血球分類試薬 | |
JP5943909B2 (ja) | 血液分析装置、血液分析方法、及びコンピュータプログラム | |
JP6001425B2 (ja) | 血球分析方法、血球分析装置およびプログラム | |
JP5881519B2 (ja) | 血液分析装置、血液分析方法、及びコンピュータプログラム | |
JP3886271B2 (ja) | 赤芽球の分類計数用試薬及び分類計数方法 | |
JP3048260B2 (ja) | 白血球分類計数用試料調製方法 | |
JP4796443B2 (ja) | 試料分析用試薬、試料分析用試薬キット及び試料分析方法 | |
JP4914656B2 (ja) | 試料分析用試薬、試料分析用試薬キット及び試料分析方法 | |
US20070231913A1 (en) | Method and apparatus for measuring hematological sample | |
JP5600726B2 (ja) | 試料分析方法 | |
EP2587262B1 (en) | Detection method of activated neutrophils and apparatus therefor | |
JPH01199161A (ja) | 白血球を定量且つ識別する方法 | |
RU2435164C2 (ru) | Реактив и набор реактивов для анализа незрелых лейкоцитов | |
WO2011140042A1 (en) | Method for hematology analysis | |
JP7291337B2 (ja) | 骨髄液分析方法、試料分析装置及びコンピュータプログラム | |
JP2017211318A (ja) | 試料分析方法、試料分析装置および試薬 | |
JP4338206B2 (ja) | 赤芽球の分類計数方法 | |
JP2002207034A (ja) | 異常細胞検出方法 | |
US20060223138A1 (en) | Method and apparatus for counting megakaryocytes | |
JP2006308574A (ja) | 巨核球の計数方法及び装置 | |
JP2012103267A (ja) | 血液学的試料の測定装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12776153 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012776153 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013027349 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013027349 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131024 |